BOLD News & Events

"With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin degrader in patients with breast cancer who are seeking new treatment options. BBI-940 is designed to disrupt ecDNA segregation and inheritance, a differentiated mechanism for targeting chromosomally unstable cancers. The Boundless team is focused on clinical execution and reaching an initial proof-of-concept readout within our existing cash runway," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.

Cash, cash equivalents, and short-term investments totaled $107.6 million as of December 31, 2025. The Company expects its cash to fund operations into the second half of 2028, through the anticipated initial clinical proof-of-concept readout from KOMODO-1.

Following a strategic portfolio review, Boundless Bio has elected to cease enrollment of the Phase 1/2 Potentiate trial evaluating the combination of BBI-355, its oral, selective CHK1 inhibitor and BBI-825, its oral, selective RNR inhibitor, in oncogene-amplified cancers. "This decision reflects market considerations, clinical data, and the Company's prioritization of programs with the greatest potential to deliver meaningful clinical impact and long-term value," the company said.

Boundless Bio announced that the U.S. Food and Drug Administration, FDA, has accepted its Investigational New Drug, IND, application for its novel Kinesin oral degrader program, BBI-940. The acceptance of the BBI-940 IND enables Boundless to advance the program into a first-in-human clinical trial for patients with metastatic breast cancer, KOMODO-1, which is expected to initiate in the first half of 2026. The Company expects to deliver initial proof-of-concept clinical data within its cash runway timeline. Based on the revised operating plan, the Company's streamlined operations will extend its operating runway into the second half of 2028, through the anticipated initial clinical proof of concept readout for BBI-940.